Comment on the intravenous tranexamic acid use in revision total joint arthroplasty
Authors He J, Liu Y
Received 26 September 2018
Accepted for publication 20 November 2018
Published 10 December 2018 Volume 2018:12 Pages 4191—4194
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 2
Editor who approved publication: Dr Georgios D. Panos
Jieyu He, Youshuo Liu
Department of Geriatrics, Second Xiangya Hospital, Central South University, Changsha 410011, China
Kuo et al thoroughly evaluated the safety and efficacy of intravenous tranexamic acid in revision total joint arthroplasty (TJA) via aspects of blood loss and transfusion, events of venous thromboembolism.1 We consider application of this drug of great value in revision TJA. However, we would like to address several concerns related to this meta-analysis.
Feng-Chih Kuo,1 Pao-Yen Lin,2 Jun-Wen Wang,1 Po-Chun Lin,1 Mel S Lee,1 Antonia F Chen3
1Department of Orthopaedic Surgery, Kaohsiung Chang Gung Memorial Hospital, College of Medicine, Chang Gung University, Kaohsiung, Taiwan; 2Department of Psychiatry, Kaohsiung Chang Gung Memorial Hospital, College of Medicine, Chang Gung University, Kaohsiung, Taiwan; 3Department of Orthopaedic Surgery, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
We read the letter from He and Liu in response to our recently published article entitled “Intravenous tranexamic acid use in revision total joint arthroplasty: a meta-analysis”1 with interest.
View the original paper by Kuo and colleagues.
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]